Efficacy and safety of Nalmefene in alcohol-dependent patients with chronic liver disease
Not Applicable
Recruiting
- Conditions
- alcohol-dependent patients
- Registration Number
- JPRN-UMIN000036655
- Lead Sponsor
- Kitasato University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patients with end-stage liver failure who have hepatic ascites, child-Pugh class BC and hepatic encephalopathy 2. Pregnant women or patients with potential pregnancy 3. Patients who research managers judged inappropriate as subjects
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in heavy drinking days (HDDs) after 24 weeks of treatment Primary outcome measures were: changes in heavy drinking days (HDDs) and total alcohol consumption (TAC, g/day).
- Secondary Outcome Measures
Name Time Method 1) changes in drinking risk level after 24 weeks of treatment 2) changes in total alcohol consumption after 24 weeks of treatment